SMC approves the first immunotherapy combination (Nivolumab combined with ipilmumab) for patients with rare-mutated advanced colorectal cancer

Nivolumab combined with ipilmumab has been approved by the Scottish Medicines Federation (SMC) as a treatment option for adult patients for the treatment of patients who have failed previous fluoropyrimidine-based chemotherapy

Recently, Bristol-Myers Squibb (BMS) announced that the Scottish Pharmaceutical Union (SMC) has accepted Nivolumab in combination with ipilmumab as a late mismatch repair defect (dMMR) or high microsatellite instability (MSIH)Treatment options for adults with colorectal cancer , these patients have failed previous fluoropyrimidine-based chemotherapy, and the therapy is used by the NHS in Scotland

This group of patients is characterized by a rare genetic mutation called MSI-H or dMMR, which affects how the cancer grows

The median age of the treated patients was 66 years (N = 45)

Original source:

https:// href="https://" target="_blank" rel="noopener">https:// https://